With regulatory scrutiny increasing, we recognize how important it is for pharmaceutical companies to have established sterile back-up supply agreements in place.
Research Triangle Park, NC (PRWEB) March 17, 2011
Patheon (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry announced today that the company will feature its sterile pharmaceutical manufacturing back-up supply program for current and potential customers at the upcoming INTERPHEX conference in New York. Patheon’s back-up sterile supply program is key to ensuring consistent and dependable supply of sterile pharmaceutical products.
Geoffrey M. Glass, Patheon’s Executive Vice President of Global Sales and Marketing stated, “With regulatory scrutiny increasing, we recognize how important it is for pharmaceutical companies to have established sterile back-up supply agreements in place. Our program brings a prudent way to manage the risk of supply interruption without building the capacity internally or committing to onerous volume obligations with a contract manufacturing partner. For pharmaceutical companies, the benefit of getting an insurance policy on their sterile supply should largely offset the tech transfer investment.”
Patheon representatives will be available to discuss the company’s back-up sterile supply program at the upcoming INTERPHEX Conference in New York, N.Y. from March 29 through March 31, 2011. The company will be exhibiting at Booth 1233 through the duration of the conference.
For those companies that are interested in discussing this program and will not be attending the conference, learn more at: http://www.patheon.com/Marketing/SterileBackup_landing_6/sterileBackup.html
Patheon is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. The company provides the highest quality products and services to approximately 300 of the world’s leading pharmaceutical and biotechnology companies. Patheon’s services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. The company uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies. Its comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon takes customers direct to clinic with global clinical packaging and distribution services and Patheon’s Quick to Clinic™ programs can accelerate early phase development projects to clinical trials while minimizing the consumption of valuable API. Through its integrated development and manufacturing network of 11 facilities and nine development centers, across North America and Europe, the company ensures that customer products can be launched on-time and with confidence anywhere in the world.